Abstract:
Objective To analyze the expression of GFRA1 in breast cancer tissues and its predictive value for therapy and prognosis by biomformatics.
Methods The GEO, TCGA, Oncomine and Kmplot databases were retrieved to include relevant studies that related to the expression of GFRA1 in breast cancer, and analyze its predictive value in chemotherapy, endocrine therapy, and prognosis.
Results GFRA1 was highly expressed in different types of breast cancer tissues (P < 0.05), positively correlated to ER and PR expression (r=0.66 and r=0.22, respectively), and negatively correlated with HER-2 and Ki-67 expression (r=-0.09 and r=-0.12, respectively). Patients with low GFRA1 expression were susceptible to tamoxifen and doxorubicin resistance. GFRA1 expression significantly correlated with the prognosis of breast cancer patients (P < 0.05), and patients with higher expression of GFRA1 survived longer than those with low expres- sion (hazard ratio < 1).
Conclusions GFRA1 is highly expressed in breast cancer tissues, and patients with low expression are resistant to tamoxifen and doxorubicin, and their prognosis is poor.